EVERSANA Patient Services: Full-Stack Commercialization Model

Company Positioning

EVERSANA positions itself as having “disrupted the commercial services industry” by creating a patient-centered model that integrates services traditionally purchased separately from multiple vendors. They serve 25 of the top 25 bio-pharmaceutical firms and 670+ bio-pharmaceutical and device customers.

Their core thesis: most drug launches miss forecast, and established brands slowly lose revenue. EVERSANA’s integrated model claims to solve this by combining “fit for purpose” solutions across the entire commercialization lifecycle.

Full Service Offering Map

EVERSANA’s services span eight major capability areas, all connected by a data and digital transformation layer:

Advisory Services — Strategic consulting on commercialization
Agency Solutions — Creative, branding, omnichannel marketing
Field Deployment Solutions — Contract sales forces, MSLs, field reimbursement
Medical Affairs — Medical information, publication planning
Market Access — Payer strategy, formulary positioning
Pricing & Reimbursement — Pricing strategy, HEOR
Patient Services & Specialty Pharmacy — Hub, copay, PAP, nursing, pharmacy
Trade, Channel & 3PL — Distribution, logistics

All underpinned by: Data, Analytics, Products & Platforms (ACTICS platform) and Digital Transformation capabilities.

The key differentiator vs. point-solution providers (like ConnectiveRx) is that EVERSANA can offer best-in-class services for specific needs, integrated solutions to overcome any challenge, or a full-scale launch or established brand revival package combining all capabilities.

Patient Services Capabilities in Detail

Access & Hub

EVERSANA’s hub offering covers the standard access and reimbursement workflow:

Patient enrollment and intake (web, EMR integration, OCR data intake automation)
Electronic Benefit Verification (eBV) via proprietary ACTICS eAccess platform
- Direct connectivity to 1,400+ payers covering 90% of U.S. covered lives
- Historical industry eBV success rate: 43% vs. EVERSANA’s 90% for both pharmacy and major medical benefits
- Real-time results reducing time-to-therapy from days to hours
- Integrates into Brand.com, CRM, or provider portals via API
Electronic Prior Authorization (ePA)
- Proprietary repository of plan- and therapy-specific PA criteria
- Pre-populates medical necessity information into customized forms
- 92-96% of electronically submitted forms accepted as complete (vs. industry 73% initial rejection rate)
- Real-time status tracking for prescribers, manufacturers, and field teams
Automated call bots to expedite payer interactions
Patient Navigator model: Dedicated case managers as single point of contact providing white-glove service

Operational model highlights:

5% staffing bench for surge capacity
OCR for efficient data intake
Evidence-based continuous improvement process
Extensive training and development programs
Robust quality monitoring

Affordability Solutions

Comprehensive copay and affordability capabilities:

Omni-channel enrollment: EHR, digital concierge, brand website (open APIs), provider/patient/SP portals, IVR, hub integration, mobile (SMS/QR code)
Advanced copay adjudication: MedxClaim (HCP-administered), debit and alternative payment vehicles, digital claim submissions, ProXeclaim
Patient eligibility management: Attestation, transaction-based management, government compliance
Digital wallet savings cards: Text-to-activate with mobile wallet integration; used by ~20% of patients
Patient Assistance Programs (PAP): Automated intake and eligibility via Business Rules Engine, electronic income validation (99% accuracy), alternate funding source screening
Reporting/analytics: Accumulator detection, fraud/waste/abuse monitoring, adherence tracking, program optimization

Adherence

Integrated digital tools for patient communication
Personalized adherence plans based on patient preferences and profile
Adherence analytics platform

Specialty Pharmacy

EVERSANA operates its own specialty pharmacy — a critical differentiator vs. hub-only providers:

Chesterfield, Missouri facility with 11,200 sq. ft. of temperature-validated dispensing/distribution space
Processing 85,000+ shipments annually with capacity for 10M+ TRx
99% dispensing accuracy, 99.8% inventory accuracy, 98% on-time shipments, 99% network coverage
Ships to all 50 states, Puerto Rico, and U.S. territories
Distinct commercial and non-commercial dispensing pharmacies
Dual pharmacist verification process (PV1 + PV2)
Therapeutic expertise: MS, immunology, dermatology, cardiovascular, respiratory, oncology, cell and gene therapy
Handles free drug programs (PAP, bridge) with special storage/handling
Automated dispensing and packing capabilities

In-Home Nursing & Clinical Support

Nationwide nursing network coverage
Telephonic nursing with clinical nurse navigators for self-injection support
VoIP telephony (Cisco) with IVR, ACD, call recording, quality assurance (Calabrio)
High-touch patient engagement and behavioral medication via live coaching

Direct-to-Patient (DTP) / Telehealth

A differentiated capability powered by partnership with Upscript Health:

End-to-end DTP platform: Patient targeting via ACTICS ML, digital engagement, virtual HCP consult, ePrescribing, benefit verification, pharmacy dispensing, adherence support
Claims to be the “industry’s first and only patient-led virtual care model”
Case study results: Chronic condition brand generating 90K+ prescriptions shipped annually; telehealth generating 20% of overall brand revenue; Patient NPS of 74
ML-powered telehealth propensity scoring to identify patients likely to use virtual care
Modular platform adaptable to different product and patient scenarios

Technology Platform: ACTICS by EVERSANA

The data and analytics backbone connecting all services:

280M+ lives in patient-finding database
300M U.S. patient records linked longitudinally across multiple data sources:
- Open & closed Rx claims (TRx, NRx, NBRx; Dx, Px; patient pay; plan pay)
- Formulary & policy data (payer, plan, formulary, tier status, restrictions, PA details)
- Affiliations (IDN, hospital, HCP, payer, performance metrics, quality metrics)
- Structured & unstructured EMR data (procedures, therapies, healthcare system progression)
- SP & hub data (pharmacy name, NPI, TRx, patient status)
- CMS open payments and Medicaid exclusion data
- Client CRM data and consulting services data
Machine learning and AI engines for:
- Patient identification before diagnosis
- Switch prediction
- Telehealth propensity scoring
- Provider segmentation
- Campaign optimization

EVERSANA ORCHESTRATE

Their omnichannel engagement platform connecting HCP and patient touchpoints:

Modular omnichannel solution “in a box” providing strategy, process, and technology powered by AI
Connects: field force, events, email, SMS, paid media, social media, brand websites, eAccess, telehealth, copay, patient communities, chatbot, call center
Digital Concierge: AI and/or live chat via web and SMS, with eBV/ePA integration, pharmacy selection, copay offer and wallet, email/SMS reminders
Chatbot: Compliant conversational AI, web/mobile/SMS compatible, embeddable on websites or triggered via QR codes

Key Differentiators EVERSANA Claims

Integration: The only commercialization partner that combines advisory, field force, marketing, patient services, specialty pharmacy, market access, and data analytics
Owned specialty pharmacy: Enables end-to-end visibility from enrollment through dispensing — eliminates the gap between hub and pharmacy that exists with independent hub providers
ACTICS data platform: 280M+ lives with ML/AI for patient finding, propensity modeling, and campaign optimization
DTP/Telehealth capability: First-mover in pharma-branded virtual care with Upscript partnership
eAccess eBV/ePA performance: 90% electronic results vs. 43% industry average; 92-96% ePA acceptance rate
Outcome-based model: Claims to generate measurable ROI through integrated data across all touchpoints

What This Tells Us About the Market

The Full-Stack vs. Point-Solution Debate

EVERSANA represents one pole of the hub services market: the fully integrated commercialization partner. The opposing model is the independent point-solution provider (e.g., ConnectiveRx). Key implications:

Bundling is the strategic direction. Both EVERSANA (from the full-stack side) and ConnectiveRx (from the point-solution side) are converging toward the same thesis: pharma companies want fewer vendors with more integrated data visibility. EVERSANA has the advantage of already owning the stack; ConnectiveRx was pursuing specialty pharmacy M&A to close the gap.
Specialty pharmacy ownership is the key differentiator. EVERSANA’s ability to track patients from enrollment through dispensing provides data continuity that hub-only providers cannot match. This is why ConnectiveRx’s PE sponsors identified specialty pharmacy as the #1 M&A priority.
Technology is becoming table stakes. eBV, ePA, OCR, chatbots, and digital enrollment are standard capabilities. The real differentiation is in data infrastructure (longitudinal patient records, ML-powered targeting) and how effectively technology connects across service lines.
The DTP/telehealth channel is emerging. EVERSANA’s investment in virtual care represents a potential paradigm shift — rather than just supporting the traditional HCP-pharmacy-patient pathway, it creates a new patient acquisition channel. If telehealth can generate 20% of brand revenue (per their case study), this becomes a significant growth vector.
Scale matters for the integrated model. EVERSANA’s approach requires massive investment across many capabilities simultaneously. This model is viable for large diversified service providers but creates a high barrier to entry. Point-solution providers compete by being deeper and more specialized in their specific domain.

Implications for Pharma Buyers

Emerging/small biotech with a single product launch may prefer the EVERSANA model for simplicity and speed
Large pharma with established vendor relationships across service lines may prefer best-of-breed point solutions (like CRx for hub, a separate copay provider, etc.) for leverage and specialization
The decision framework increasingly comes down to: Do you want one vendor with integrated data, or multiple specialized vendors that you must integrate yourself?

Sources

EVERSANA Patient Services General Capabilities Deck, 2024 (49 pages)
InTouch Group acquisition by EVERSANA referenced in ConnectiveRx IC memos (TEV $975M, 21.3x EBITDA, Oct 2021)